Financial Shenanigans
Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.
The Forensic Verdict
Elixirr's headline numbers are not fabricated, but they are heavily polished. Operating cash flow is real, capex is genuinely trivial, the auditor (Crowe U.K. LLP) has issued a clean opinion, and there is no restatement, regulatory action, or short-seller report on file. What raises risk is the gap between what management foregrounds — Adjusted EBITDA, free cash flow, organic growth — and what the statutory P&L and balance sheet show: net-income margins compressing from 20% to 13% in two years, free cash flow fully consumed by acquisitions in 4 of the last 5 years, intangibles now 79% of total assets, a $56.8M contingent-consideration liability sitting on a 77% probability-of-maximum assumption, and a Main Market debut paired with a swing from $9.4M net cash to $38.2M net debt. None of those facts is hidden — but each pulls in the opposite direction from the "industry-leading profitability, strong cash generation" framing. The single data point that would most change the grade is whether organic growth holds up next year without a fresh acquisition; if it does, several yellow flags collapse. Forensic Risk Score: 48 / 100 — Elevated.
Forensic Risk Score (0-100)
Red Flags
Yellow Flags
3-yr CFO / Net Income
3-yr FCF / Net Income
FCF after acquisitions FY25 ($M)
Adj EBITDA premium to GAAP op income (FY25)
Intangibles as % of total assets (FY25)
Shenanigans scorecard — all 13 categories
The two genuinely red items — M&A-distorted cash flow and a widening non-GAAP gap — are linked. As acquisition cadence has accelerated, both the items management is allowed to add back (acquired intangible amortisation, contingent-consideration movements, deal costs) and the items it chooses to add back (share-based payments) have grown disproportionately. The result is an Adjusted EBITDA that beats the statutory operating line by half, and a free-cash-flow figure that disappears once the cash spent on acquiring the businesses generating that EBITDA is subtracted.
Breeding Ground
The governance setup amplifies the accounting risk rather than dampening it. Stephen Newton, the founder CEO, owns 22.85% of the shares and approved the FY25 directors' report; his and co-founder Graham Busby's combined $3.75M FY25 variable remuneration is roughly four times their combined base salary, and the underlying performance targets are explicitly withheld as commercially sensitive. The Remuneration Committee did not engage an external consultant in FY25, and the company is openly non-compliant with three UK Corporate Governance Code provisions covering vesting periods, malus and clawback. Crowe U.K. LLP has audited Elixirr for seven years; that is sub-tenure-rotation but worth tracking after the recent move from AIM to the Main Market, which raises the company's regulatory and reporting bar.
The breeding-ground score is yellow, not red, because the founder is on the same side of the equity stack as ordinary shareholders (11.4M-share direct holding, eight-figure economic interest). But the lack of malus/clawback means there is no formal mechanism to recoup variable pay if a future restatement materialises, and the discretionary nature of bonus targets weakens the link between disclosed performance metrics and disclosed remuneration. Three UK Code non-compliances stacked on a first-year Main Market filer is the kind of profile that institutional governance teams will keep flagging until the regime tightens.
Earnings Quality
Earnings exist, but their quality is deteriorating in two ways the headline metric hides. First, the gap between the Adjusted EBITDA management points to and the statutory operating profit has widened from 12% (FY23) to 49% (FY25). Second, statutory net-income margin has compressed from 20% to 13% over the same window, even as Adjusted EBITDA margin has held at 28-30%. Both moves are driven by the same underlying mechanic: acquired-intangible amortisation, share-based payments, and contingent-consideration movements are growing faster than revenue, and they are being routinely excluded from the headline.
Adjusted vs statutory profitability — the gap is widening
The Adjusted EBITDA margin line is flat at 28-30% — the picture management presents. The statutory operating margin has fallen 640bp in two years (26.3% → 19.9%), and the statutory net margin has fallen 690bp (20.1% → 13.2%). The drivers are visible in note 3 of the FY25 accounts: amortisation of acquired intangibles, share-based payment charges ($6.3M, +90% YoY), Main Market listing costs, acquisition-related professional fees, and movements in contingent-consideration fair value. Calling these "adjusting items" in a serial acquirer where the next deal is already announced (Kvadrant, January 2026) is a definitional choice, not a statement of fact.
Adjusted Diluted EPS premium has tripled
The 58% premium of Adjusted EPS over statutory EPS in FY25 is large by professional-services-rollup standards. Investors anchoring on the $0.79 Adjusted Diluted EPS figure are anchoring on a number that bears progressively less relation to the $0.50 reported under IFRS.
Receivables vs revenue — DSO has drifted, even after FY25 strong-collections base
DSO has migrated from 50 days in FY20 to 67 days in FY25. The FY24 step-down to 62 days was a clean collections result that management explicitly acknowledged would reverse, which it did. The auditor (Crowe) flagged revenue recognition as a Key Audit Matter in FY25, with specific concern about Group components that "did not operate a timesheet system" — meaning some entities recognise services revenue based on management estimates of effort rather than measured time. That is normal in consulting after acquisitions but it is a judgmental area worth noting alongside the DSO drift.
Cash Flow Quality
Operating cash flow is genuine — the company collects cash from its services, working capital is normal for consulting, and capex is essentially zero. The forensic problem is that management's "strong cash generation" framing materially overstates how much cash is left for shareholders once the cash needed to acquire the next year's growth has been spent.
Three lines tell the story: CFO, FCF, and FCF after acquisitions
In FY22, FY23, FY24 and FY25, acquisitions consumed 116%, 90%, 72% and 110% of operating cash flow respectively. FCF after acquisitions has been negative twice (FY22, FY25) and below $13M four times in the last five years. The 11% FCF growth management celebrates in FY25 ($35.2M → $41.9M, the company-defined FCF includes lease repayments) sits next to a FCF-after-acquisitions of negative $4.6M and an $80.8M debt issuance to fund the TRC purchase and earn-outs. The economic free cash flow for shareholders, after replenishing the inorganic engine that drives 13-15 percentage points of the headline 34% revenue growth, is materially lower than the figure reported.
Working-capital contribution and the FY24 collections reset
FY24 was the year working-capital and non-cash items contributed $8.1M of CFO above pre-tax profit, driven by the December 2024 collections push management has now disclosed. FY23 was the inverse — CFO ran $6.7M below pre-tax profit because of receivables build. This volatility means single-year CFO/NI ratios are misleading. The 3-year averaged CFO/NI is 1.66, which is healthy for a consultancy, but it understates the cyclicality: the band runs from 0.97 (FY23) to 1.79 (FY24).
Net cash to net debt — the FY25 inflection
Cash has fallen every year since FY21, despite Adjusted EBITDA quadrupling. $80.8M of new debt was issued in FY25; of that, $39.3M funded TRC, $18.4M went to EBT share buybacks (offsetting employee dilution), and $9.7M went to earn-out and holdback payments on prior deals. The remainder rolls forward to fund FY26 commitments including Kvadrant ($24.2M maximum consideration) and the residual TRC contingent consideration ($56.8M on the balance sheet at year-end on a 77%-of-max probability assumption). The company is moving from a self-funded growth model to a debt-funded one, which is a different risk profile than the "strong cash generation" framing suggests.
Metric Hygiene
Management's KPI panel is consistent year-on-year, but it is also constructed in a way that systematically drops the metrics where the company is doing worst. Net debt does not appear in the FY25 highlights panel; statutory EPS does not; goodwill-to-equity does not; FCF-after-acquisitions does not. What appears is Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Profit Before Tax, Adjusted Diluted EPS, dividend per share, free cash flow (defined inclusively of lease payments), and revenue. The metrics dropped from headline disclosure are exactly the metrics that have moved adversely. This is the textbook "showcasing misleading metrics" pattern — not because any individual disclosure is wrong, but because the curated set is asymmetric.
The two metrics most worth recalibrating before underwriting: (1) statutory EPS is now $0.50, not $0.79, and the gap is widening; (2) free cash flow available to shareholders, after the M&A engine, is single-digit millions, not $41.9M. The other metrics are honest if you read the small print, but a reader who looks only at the highlights panel will form a materially different view than one who reads the cash-flow statement and note 3.
Soft assets are now most of the balance sheet
Of the $265.7M intangibles balance, $232.7M is goodwill — a single line item the auditor flagged as a Key Audit Matter, with management's impairment model resting on long-term growth and discount-rate assumptions. With statutory operating income at $40.0M, a single goodwill impairment event of even 10% would wipe a year's reported operating profit. The risk is not that an impairment is imminent — there is no audit signal it is — but that the carrying value of goodwill has grown faster than the underlying earnings power, narrowing the cushion.
What to Underwrite Next
The forensic risk here is not a thesis-breaker. It is a valuation and position-sizing question — specifically, whether to value the business on its statutory P&L (where margins are compressing and EPS growth is decelerating) or on its Adjusted EBITDA (where margins are stable and growth is intact). The honest answer for FY26 underwriting is somewhere in between, with explicit dollar adjustments rather than a blanket trust in either number.
Five forensic items to track in the next four reporting periods:
Organic revenue growth in H1 FY26 without a fresh acquisition. Management says 15.3% organic. If H1 FY26 prints below 10% with no integration distortions, the "growth-accretion mix" thesis weakens and the Adjusted multiple is overpaid.
DSO at the H1 FY26 interim. A reading above 70 days, especially with a TRC mix that should structurally lower DSO, would signal client-payment friction or aggressive revenue recognition.
Contingent-consideration outcome on the 77%-of-max TRC earnout. If the actual payment exceeds the booked liability, FY26 statutory profit takes a fair-value hit. If it falls short, expect a credit (and watch for inclusion in adjusted earnings).
Goodwill impairment commentary in the FY26 audit report. Crowe has flagged this as a KAM two years running. Any change in CGU definition, discount rate, or terminal growth assumption that produces materially smaller headroom is a yellow-to-red signal.
Net debt trajectory. $32.5M at FY25 end; $24.2M Kvadrant maximum consideration plus residual TRC payments due. If net debt at H1 FY26 is above $54M without a clear deleveraging path, the equity-buyback-funded EBT mechanism becomes harder to sustain alongside the dividend.
A signal that would upgrade the grade: the FY26 results show statutory operating margin recovering toward 24%+, Adjusted EBITDA premium narrowing, FCF after acquisitions positive in both halves, and DSO normalising below 60 days. A signal that would downgrade the grade: any auditor change, a restatement of contingent-consideration accounting, statutory net income flat or down on rising revenue, or a goodwill impairment.
For position sizing: treat Adjusted EBITDA at a 10-15% discount (to re-add normalised SBP), use FCF after acquisitions for yield calculations, and apply a goodwill-concentration haircut to book value. The forensic risk does not warrant exclusion — it warrants a smaller position, a clearer monitoring cadence, and a willingness to act if any two of the five tracked items move adversely in the same period.
The accounting risk at Elixirr is real, recurring, and well-disclosed once you go past the highlights panel. It is not a fraud signal. It is a serial-acquirer signal: M&A drives the headline numbers, the headline numbers are then adjusted up to hide the dilution and amortisation cost of that M&A, and the cycle repeats. Investors who model the company on FCF-after-acquisitions and statutory EPS will arrive at a defensible valuation; investors who model it on Adjusted EBITDA and management-defined free cash flow will pay a premium they may not realise they are paying.